SIGA trades at Wall Street's consensus target of —.
Last 12 months price action with 12-month analyst target path
The base valuation assumes SIGA achieves its forward estimates and maintains a stable P/E multiple of 1.8x. This scenario reflects the blended consensus of 1 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 8, 2026, SIGA Technologies, Inc. (SIGA) has a Wall Street consensus price target of N/A, based on estimates from 1 covering analysts. The company has a market capitalization of $222M.
Analyst price targets range from a low of N/A to a high of N/A.
The current analyst consensus rating is Buy, with 1 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, SIGA trades at a trailing P/E of -80.9x and forward P/E of 1.8x. Analysts expect EPS to grow +4538.6% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $1.41, with bear and bull scenarios of $0.89 and $1.86 respectively. Model confidence stands at 38/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 GILDGilead Sciences, Inc. | $207.2B | $166.89 | $165.38 | -0.9% | Buy | — | 58 |
 AVTXAvalo Therapeutics, Inc. | $382M | $6.93 | $35.13 | +406.9% | Buy | — | 10 |
 AGENAgenus Inc. | $298M | $7.15 | $25.00 | +249.7% | Buy | 26.7x | 12 |
 VRTXVertex Pharmaceuticals Incorporated | $138.9B | $547.09 | $580.20 | +6.1% | Buy | 30.0x | 56 |
 REGNRegeneron Pharmaceuticals, Inc. | $93.2B | $904.35 | $887.79 | -1.8% | Buy | 13.4x | 49 |
 MNKDMannKind Corporation | $1.2B | $3.90 | $10.00 | +156.4% | Buy | — | 21 |
 BAXBaxter International Inc. | $13.3B | $25.79 | $23.83 | -7.6% | Hold | 12.3x | 36 |
 MCKMcKesson Corporation | $123.8B | $1060.84 | $983.13 | -7.3% | Buy | 23.8x | 31 |
 CAHCardinal Health, Inc. | $63.6B | $271.72 | $279.33 | +2.8% | Buy | 21.6x | 33 |
 NVAXNovavax, Inc. | $1.8B | $10.78 | $18.00 | +67.0% | Buy | — | 23 |
Quick answers to the most common questions about buying SIGA stock.
The consensus price target for SIGA is $N/A, close to the current price of $3.1 (N/A% implied move). Based on 1 analyst estimates, the stock appears fairly valued near current levels.
SIGA has a consensus rating of "Buy" based on 1 Wall Street analysts. The rating breakdown is predominantly bullish, with 1 Buy/Strong Buy ratings. The consensus 12-month price target of $N/A implies N/A% upside from current levels.
With a forward P/E of 1.8235x, SIGA trades at a relatively low valuation. The consensus target of $N/A implies N/A% appreciation, suggesting the market may be pricing in risks.
The most bullish Wall Street analyst has a price target of $N/A for SIGA, while the most conservative target is $N/A. The consensus of $N/A represents the median expectation. Our quantitative valuation model projects a bull case target of $2 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
SIGA is lightly followed, with 1 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 1 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month SIGA stock forecast based on 1 Wall Street analysts shows a consensus price target of $N/A, with estimates ranging from $N/A (bear case) to $N/A (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $1, with bear/bull scenarios of $1/$2.
Our quantitative valuation model calculates SIGA's fair value at $1 (base case), with a bear case of $1 and bull case of $2. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 38/100.
SIGA trades at a forward P/E ratio of 1.8x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
SIGA appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $N/A target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
SIGA analyst price targets range from $N/A to $N/A, a NaN% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $N/A consensus represents the middle ground. Our model's $1-$2 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.